Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Long Tang

Showing results (561-570 of 575) with videos related to

Pageof 58
Sort By:
The Lancet. Oncology|October 1, 2016
Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trialYing Sun, Wen-Fei Li, Nian-Yong Chen, et al.
International Journal of Cancer|January 8, 2019
Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long-term results of phase 3 randomized controlled trialWen-Fei Li, Nian-Yong Chen, Ning Zhang, et al.
Cancer Cell|January 19, 2024
Refining the 8th edition TNM classification for EBV related nasopharyngeal carcinomaXiao-Jing Du, Gao-Yuan Wang, Xiao-Dong Zhu, et al.
Lancet (London, England)|June 10, 2021
Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trialYu-Pei Chen, Xu Liu, Qin Zhou, et al.
Nature Cancer|July 1, 2026
Long-term outcomes of adjuvant metronomic capecitabine in locoregionally advanced nasopharyngeal carcinoma: a randomized, controlled, multicenter, phase 3 studyYa-Lan Tao, Dong-Hong Wu, Qin Zhou, et al.
Cancer Communications (London, England)|October 26, 2021
The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinomaLing-Long Tang, Yu-Pei Chen, Chuan-Ben Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2022
Final Overall Survival Analysis of Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma: A Multicenter, Randomized Phase III TrialYuan Zhang, Lei Chen, Guo-Qing Hu, et al.
Nature|March 12, 2026
Risk-adaptive therapy guided by dynamic ctDNA in nasopharyngeal carcinomaJiawei Lv, Dan-Xue Zheng, Jin-Hui Liang, et al.
The New England Journal of Medicine|June 1, 2019
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal CarcinomaYuan Zhang, Lei Chen, Guo-Qing Hu, et al.
The Lancet. Oncology|September 4, 2025
Target volume delineation of the neck for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlasLing-Long Tang, Cheng-Long Huang, Shao-Jun Lin, et al.
Pageof 58

Showing results (561-570 of 575) with videos related to

Sort By:
Pageof 58
The Lancet. Oncology|October 1, 2016
Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trialYing Sun, Wen-Fei Li, Nian-Yong Chen, et al.
International Journal of Cancer|January 8, 2019
Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long-term results of phase 3 randomized controlled trialWen-Fei Li, Nian-Yong Chen, Ning Zhang, et al.
Cancer Cell|January 19, 2024
Refining the 8th edition TNM classification for EBV related nasopharyngeal carcinomaXiao-Jing Du, Gao-Yuan Wang, Xiao-Dong Zhu, et al.
Lancet (London, England)|June 10, 2021
Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trialYu-Pei Chen, Xu Liu, Qin Zhou, et al.
Nature Cancer|July 1, 2026
Long-term outcomes of adjuvant metronomic capecitabine in locoregionally advanced nasopharyngeal carcinoma: a randomized, controlled, multicenter, phase 3 studyYa-Lan Tao, Dong-Hong Wu, Qin Zhou, et al.
Cancer Communications (London, England)|October 26, 2021
The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinomaLing-Long Tang, Yu-Pei Chen, Chuan-Ben Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2022
Final Overall Survival Analysis of Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma: A Multicenter, Randomized Phase III TrialYuan Zhang, Lei Chen, Guo-Qing Hu, et al.
Nature|March 12, 2026
Risk-adaptive therapy guided by dynamic ctDNA in nasopharyngeal carcinomaJiawei Lv, Dan-Xue Zheng, Jin-Hui Liang, et al.
The New England Journal of Medicine|June 1, 2019
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal CarcinomaYuan Zhang, Lei Chen, Guo-Qing Hu, et al.
The Lancet. Oncology|September 4, 2025
Target volume delineation of the neck for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlasLing-Long Tang, Cheng-Long Huang, Shao-Jun Lin, et al.
Pageof 58